L-NMMA (citrate) (Synonyms: L-NG-monomethyl Arginine citrate) |
| Catalog No.GC11163 |
relatively non-selective inhibitor of all NOS isoforms
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
L-NMMA (citrate) is a relatively non-selective inhibitor of all NOS isoforms [1].
Nitric oxide synthases (NOSs) belong to a family of enzymes involved in catalyzing the production of nitric oxide (NO) from L-arginine. As an important cellular signaling molecule, NO has been implicated in modulating vascular tone, insulin secretion, airway tone, and peristalsis, angiogenesis and neural development. Until now, three isozymes of NOS have been identified: eNOS (endothelial NOS), nNOS (neuronal NOS), and iNOS (inducible NOS). The eNOS plays a critical role in embryonic heart development and morphogenesis of coronary arteries and cardiac valves. The nNOS functions as a retrograde neurotransmitter important in long term potentiation and has been involved in the development of nervous system. The iNOS produces large amounts of NO as a defense mechanism and is an important factor in the response of the body to attack by parasites, bacterial infection, and tumor growth [2].
L-NMMA inhibited the activity of NOS with the Ki values of approximately 0.18, 0.4, and 6 μM for nNOS (rat), eNOS (human), and iNOS (mouse), respectively [1]. In perfused dog mesenteric artery segments, treatment with L-NMMA increased the vasoconstriction induced by adrenergic nerve stimulation. In dog cerebral artery strips, L-NMMA suppressed the relaxant response to transmural nerve stimulation [3]. In patients with cardiogenic shock, L-NMMA administration is safe and has favorable clinical and hemodynamic effects [4].
References:
[1] Frey C, Narayanan K, McMillan K, et al. L-thiocitrulline. A stereospecific, heme-binding inhibitor of nitric-oxide synthases[J]. Journal of Biological Chemistry, 1994, 269(42): 26083-26091.
[2] Stuehr D J, Griffith O W. Mammalian nitric oxide synthases[J]. Advances in Enzymology and Related Areas of Molecular Biology, Volume 65, 2006: 287-346.
[3] TODA N, OKAMURA T. Modification by L-NG-monomethyl arginine (L-NMMA) of the response to nerve stimulation in isolated dog mesenteric and cerebral arteries[J]. The Japanese Journal of Pharmacology, 1990, 52(1): 170-173.
[4] Cotter G, Kaluski E, Blatt A, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock[J]. Circulation, 2000, 101(12): 1358-1361.
| Cas No. | SDF | ||
| Synonymes | L-NG-monomethyl Arginine citrate | ||
| Chemical Name | N5-[imino(methylamino)methyl]-L-ornithine, citrate | ||
| Canonical SMILES | CN([H])/C(N([H])CCC[C@@H](C(O)=O)N)=N/[H].OC(CC(O)=O)(C(O)=O)CC(O)=O | ||
| Formula | 3[C7H16N4O2] · C6H8O7 | M.Wt | 756.8 |
| Solubility | ≤6mg/ml in PBS | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3214 mL | 6.6068 mL | 13.2135 mL |
| 5 mM | 0.2643 mL | 1.3214 mL | 2.6427 mL |
| 10 mM | 0.1321 mL | 0.6607 mL | 1.3214 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 14 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *